TN2011000638A1 - Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid - Google Patents

Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Info

Publication number
TN2011000638A1
TN2011000638A1 TNP2011000638A TN2011000638A TN2011000638A1 TN 2011000638 A1 TN2011000638 A1 TN 2011000638A1 TN P2011000638 A TNP2011000638 A TN P2011000638A TN 2011000638 A TN2011000638 A TN 2011000638A TN 2011000638 A1 TN2011000638 A1 TN 2011000638A1
Authority
TN
Tunisia
Prior art keywords
methyl
benzazepin
tetrazol
tetrahydro
trifluoromethyl
Prior art date
Application number
TNP2011000638A
Other languages
English (en)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2011000638A1 publication Critical patent/TN2011000638A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2011000638A 2009-06-30 2011-12-13 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid TN2011000638A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
TN2011000638A1 true TN2011000638A1 (en) 2013-05-24

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2011000638A TN2011000638A1 (en) 2009-06-30 2011-12-13 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Country Status (37)

Country Link
US (2) US8299060B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
TWI627167B (zh) * 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
RU2627361C2 (ru) 2013-01-31 2017-08-07 Чонг Кун Данг Фармасьютикал Корп. Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
EP3795695A1 (en) 2014-07-30 2021-03-24 F. Hoffmann-La Roche AG Genetic markers for predicting responsiveness to therapy
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CZ20032898A3 (cs) 2001-04-30 2004-07-14 Pfizer Products Inc. Způsob výroby inhibitorů CETP
SK2332004A3 (en) 2002-08-30 2004-12-01 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
EP1556047A4 (en) 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2004078730A2 (en) 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
MX2011014024A (es) 2012-04-20
TW201113275A (en) 2011-04-16
US8329688B2 (en) 2012-12-11
PE20120538A1 (es) 2012-05-09
US8299060B2 (en) 2012-10-30
US20120058990A1 (en) 2012-03-08
HRP20130950T1 (hr) 2013-11-22
IL216655A0 (en) 2012-02-29
BRPI1011931A2 (pt) 2016-04-19
DK2448933T3 (da) 2013-10-07
CA2764425A1 (en) 2011-01-06
EA201270099A1 (ru) 2012-05-30
JP5689875B2 (ja) 2015-03-25
EA020600B1 (ru) 2014-12-30
ES2435293T3 (es) 2013-12-18
JO2867B1 (en) 2015-03-15
MY157121A (en) 2016-05-13
EP2448933A1 (en) 2012-05-09
CL2011003263A1 (es) 2012-07-27
WO2011002696A1 (en) 2011-01-06
CN102639528B (zh) 2014-07-16
NZ596820A (en) 2013-07-26
CO6480934A2 (es) 2012-07-16
IL216655A (en) 2015-02-26
PL2448933T3 (pl) 2014-01-31
US20100331309A1 (en) 2010-12-30
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
AU2010266537B2 (en) 2013-04-18
CA2764425C (en) 2015-01-06
ECSP11011551A (es) 2012-01-31
PT2448933E (pt) 2013-10-29
AU2010266537A1 (en) 2012-02-02
UA109409C2 (ru) 2015-08-25
KR101404893B1 (ko) 2014-06-20
AR077208A1 (es) 2011-08-10
MA33385B1 (fr) 2012-06-01
DOP2011000405A (es) 2012-01-15
KR20120027426A (ko) 2012-03-21
JP2012532106A (ja) 2012-12-13
SG177413A1 (en) 2012-02-28
EP2448933B1 (en) 2013-08-28
TWI450896B (zh) 2014-09-01
ZA201108707B (en) 2013-05-29
CN102639528A (zh) 2012-08-15
CR20110669A (es) 2012-03-16
GT201100321A (es) 2012-11-15
SI2448933T1 (sl) 2013-11-29

Similar Documents

Publication Publication Date Title
TN2011000638A1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MY153985A (en) Aminotriazole derivatives as alx agonists
SI2576523T1 (sl) Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
MX342440B (es) Derivados fluorados de aminotriazol.
UA105788C2 (uk) Натрієва сіль 5-циклопропіл-2-{[2-(2,6-дифторфеніл)піримідин-5-іл]аміно}бензойної кислоти як інгібітори dhodh
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2006051314A8 (en) Guanidine derivatives as inhibitors of ddah
CY1114514T1 (el) Τrανs-4-[[(5s)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1η-1-βενζαζεπιν-1 -υλ]μεθυλ]-κυκλοεξανο-καρβοξυλικο οξυ
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
SI2125761T1 (sl) Nov postopek za sintezo pramipeksola in njegovih farmacevtsko sprejemljivih soli
TH115567A (th) ทรานส์-4-[[(5s)-5-[[[3,5-บิส(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล](2-เมธิล-2h-เททราโซล-5-อิล)อะมิโน]-2,3,4,5-เททราไฮโดร-7,9-ไดเมธิล-1h-1-เบนแซซีพิน-1-อิล]เมธิล]-ไซโคลเฮกเซนคาร์บอกซิลิค แอซิด
NZ624621A (en) Manufacturing process for pyrimidine derivatives
HK1161879A (en) Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof
PL2118095T3 (pl) Sposób wytwarzania zolmitriptanu